Phosphodiesterase 4 Inhibitors

Phosphodiesterase 4 Inhibitor

Arthritis, Psoriatic

<section class="Section" data-sectioncode="34089-3"><a name="SB110"></a><a name="section-10"></a><p></p><h1>11  DESCRIPTION</h1><p class="First">The active ingredient in OTEZLA tablets is apremilast. Apremilast is a phosphodiesterase 4 (PDE4) inhibitor. Apremilast is known chemically as N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide. Its empirical formula is C<span class="Sub">22</span>H<span class="Sub">24</span>N<span class="Sub">2</span>O<span class="Sub">7</span>S and the molecular weight is 460.5.</p><p>The chemical structure is:</p><p><img alt="Otezla Chemical Structure" src="otezla-01.jpg"/></p><p>OTEZLA tablets are supplied in 10-, 20-, and 30-mg strengths for oral administration.  Each tablet contains apremilast as the active ingredient and the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide red, iron oxide yellow (20 and 30 mg only) and iron oxide black (30 mg only).</p></section>

OTEZLA

apremilast

apremilast 10 MG Oral Tablet

Otezla

apremilast 10 MG Oral Tablet [Otezla]

apremilast 20 MG Oral Tablet

apremilast 20 MG Oral Tablet [Otezla]

apremilast 30 MG Oral Tablet

apremilast 30 MG Oral Tablet [Otezla]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event

Prescribing Information

Submit MSL Request 

Pharmacy List 

Billing and Coding Guide 

Online Sample Form 

Coverage Authorization Request 

Coverage Authorization Appeals

Letter of Medical Necessity: English

Letter of Medical Necessity: Spanish 

Prior Authorization Checklist 

Otezla HCP Request Form 

Otezla Specialty Pharmacy Start form (if HCP office wants SP to co-ordinate PA) 

Otezla SupportPlus Program 

Otezla SupportPlus Program (PsA & PsO) - Online 

Enroll in Patient Savings Program 

Formulary Information: PsO & PsA 

Other HCP Resources 

Patient Starter Kit/Brochure

Plaque Psoriasis Symptom Tracker 

PsA Symptom Tracker 

How To Start Patients on Otezla 

About Otezla: PsO

Side Effects: PsO

Patient Stories: PsO

Before & After: PsO

Doctor Discussion Guide: PsO

FAQs: PsO & PsA

Taking Otezla: PsO

Otezla Patient Roadmap (Getting Your Otezla Prescription)

Instructions For Use: PsO

About Otezla: Oral Ulcers in Bechet's Disease

Instructions For Use: Oral Ulcers in Bechet's Disease

About Otezla: PsA

Patient Stories: PsA

Doctor Discussion Guide: PsA

Taking Otezla: PsA

Side Effects: PsA

Instructions For Use: PsA